Preclinical Development Of A Humanised Antibody To C5aR.
Funder
National Health and Medical Research Council
Funding Amount
$124,875.00
Summary
Complement factor C5a is one of the most potent inflammatory mediators in the body. We have developed a monoclonal antibody that blocks the C5a receptor in vitro, and completely shuts down disease in a mouse model of rheumatoid arthritis. We plan to develop this promising new antibody into a potent therapy to treat a range of chronic and acute inflammatory diseases. The antibody has been humanised and this will be tested in three models of inflammation (rheumatoid arthritis, sepsis and colitis) ....Complement factor C5a is one of the most potent inflammatory mediators in the body. We have developed a monoclonal antibody that blocks the C5a receptor in vitro, and completely shuts down disease in a mouse model of rheumatoid arthritis. We plan to develop this promising new antibody into a potent therapy to treat a range of chronic and acute inflammatory diseases. The antibody has been humanised and this will be tested in three models of inflammation (rheumatoid arthritis, sepsis and colitis) to determine the efficacy of the antibody, safety, the most effective dose, timing and route of administration. These studies are a necessary prelude to human clinical trials, which we hope to perform in approximately 24 months.Read moreRead less
We will conduct a clinical trial of the effectiveness of a continuous auditory display of an anesthetized patient's respiratory status. Expired carbon dioxide monitoring has helped reduce respiratory incidents since its widespread introduction in the late 1980s, but a continuous auditory display of respiratory status may reduce incidents further. We will conduct a clinical trial with 10 anaesthetists of continuous auditory respiratory monitoring. Successful outcome may lead to commercial uptake.
Proof Of Concept Studies On A Novel Class Of Antibiotics
Funder
National Health and Medical Research Council
Funding Amount
$199,700.00
Summary
The rise of drug-resistant superbugs is a major healthcare concern in hospitals across the world. New antibiotics are needed to combat infections caused by bacteria that are resistant to current drugs. One collaborative team of researchers is addressing the issue. They have discovered a new compound effective against Staphylococcus aureus, the cause of Golden Staph. Using a combination of scientific disciplines the team are now developing this compound into a new antibiotic.
New Technologies For Hierarchial Shotgun Sequencing Of Recalcitrant And Repetitive DNA
Funder
National Health and Medical Research Council
Funding Amount
$79,750.00
Summary
Many repetitive regions of genomes are difficult to sequence and to assemble. �Sequencing Aided by Mutation� (SAM) is a new sequencing technology, which overcomes many of the difficulties that hinder current sequencing methods. SAM involves forming randomly mutated copies of the target DNA. These copies can then be sequenced and new mathematical tools permit the original target sequence to be revealed from the mutant copies. Here the technology will be developed to aid sequencing of long repetit ....Many repetitive regions of genomes are difficult to sequence and to assemble. �Sequencing Aided by Mutation� (SAM) is a new sequencing technology, which overcomes many of the difficulties that hinder current sequencing methods. SAM involves forming randomly mutated copies of the target DNA. These copies can then be sequenced and new mathematical tools permit the original target sequence to be revealed from the mutant copies. Here the technology will be developed to aid sequencing of long repetitive DNA fragments in genomes.Read moreRead less
Rapid HIV-1 Tropism Testing Using Novel, Soluble Mimics Of The HIV-1 Coreceptors CCR5 And CXCR4
Funder
National Health and Medical Research Council
Funding Amount
$163,426.00
Summary
This proposal seeks to develop an inexpensive assay to determine whether HIV patients will benefit from treatment with new drugs referred to as CCR5 antagonists. These are effective against HIV strains that use the CCR5 coreceptor, therefore a patient�s HIV coreceptor usage must be assessed before commencing therapy. Current assays are complicated, slow and expensive. Using novel, soluble mimics of the coreceptors we will develop an ELISA based test that can be operated using standard equipment.
Synthesis And Purification Of Flavivirus-specific Antiviral Factor Mrasal
Funder
National Health and Medical Research Council
Funding Amount
$140,000.00
Summary
In this proposal we suggest to develop an anti-flaviviral compound based on naturally occurring host factors associated with inborn flavivirus resistance observed in mice. We propose to synthesise and purify a mouse protein factor encoded by a gene (Mrasal), which we have previously mapped by mouse genetics and positional cloning to a narrow 300 kb chromosomal region on mouse chromosome 5 carrying flavivirus resistance locus (Flv). When this mouse gene was isolated, sub cloned into a mammalian e ....In this proposal we suggest to develop an anti-flaviviral compound based on naturally occurring host factors associated with inborn flavivirus resistance observed in mice. We propose to synthesise and purify a mouse protein factor encoded by a gene (Mrasal), which we have previously mapped by mouse genetics and positional cloning to a narrow 300 kb chromosomal region on mouse chromosome 5 carrying flavivirus resistance locus (Flv). When this mouse gene was isolated, sub cloned into a mammalian expression vector pcDNA3tag and transiently transfected and expressed in cos-7 and Vero cells, its product conferred antiviral effect to a flavivirus Murray Valley encephalitis (MVE), but not to a non-flavivirus encephalomyocarditis virus (EMCV). Mrasal protein operates as an antiviral host factor and confers a flavivirus specific resistance at the cellular level. It could be directly used for the treatment-cure of acute flavivirus infections in vivo. Our aims are to produce and purify the Mrasal protein for the in vivo delivery as a therapeutic compound into susceptible mice during the acute phase of flavivirus infection: 1. To synthesise and purify Mrasal protein using baculovirus system. 2. To encapsulate the protein into liposomes ready to be used in mice. 3. To perform initial testing in a limited number of susceptible mice.Read moreRead less
NaviGAIT: New Software To Simplify Interpretation Of Gait Analysis Data
Funder
National Health and Medical Research Council
Funding Amount
$179,905.00
Summary
NaviGAIT is a new software package to support interpretation of gait analysis data. It is based upon Gait Profiling, a new technique to reduce the complexity of such data. At present data intepretation is restricted to a few expert clinicians. The new software will allow non-expert clinicians to interpret data and hence make gait analysis more accessible, cheaper and more clincally useful. A module of NaviGAIT specifically for children with cerebral palsy will be the first to be developed.
Development Of A PET Detection System Prototype With Depth Of Interaction Capability
Funder
National Health and Medical Research Council
Funding Amount
$360,906.00
Summary
This development project invovles the development of a slim-line Positron Emission Tomogrphy (PET) detection sub-module, the crucial component of PET scanners, that is small and extremely flexible. It is planned to utilize this module in the design of customized new commercial PET scanners ideal for diagnosing human brain and breast disorders. The development will proceed in collaboration with Insight Oceania-ADAC, Sydney. Insight Oceania-ADAC are very excited by the potential applications and f ....This development project invovles the development of a slim-line Positron Emission Tomogrphy (PET) detection sub-module, the crucial component of PET scanners, that is small and extremely flexible. It is planned to utilize this module in the design of customized new commercial PET scanners ideal for diagnosing human brain and breast disorders. The development will proceed in collaboration with Insight Oceania-ADAC, Sydney. Insight Oceania-ADAC are very excited by the potential applications and future markets (Australia and overseas) of the newly developing PET detection sub-modules for dedicated PET scanners. Positron Emission Tomography (PET) is a functional imaging tool, which is able to quantify physiological and biochemical processes in vivo, using short-lived cyclotron-produced radiotracers. PET is emerging as an extremely important diagnostic procedure used in the early detection of cancers, neurological diseases and as an aid in treatment monitoring and drug development. The unique advantage of PET over anatomical imaging techniques, such as X-ray CT and MRI, arises from its ability to measure changes in tumour biology, at the molecular level, prior to anatomical changes in involved tissues, using trace amounts of a radiolabelled compound (radiotracer). The full potential of PET however, is not being completely utilized due to constraints within the current designs of PET scanners. When used to its full potential PET, in principle, would be an excellent diagnostic and treatment monitoring tool for breast cancer, brain tumours and other neurological conditions such as epilepsy, Alzheimer's, Parkinson's disease, post stress disorder, dementia, and depression. Lack of flexibility in current PET scanner designs to date has meant that no commercial human brain or breast imaging scanners exist. Pilot project data proved the feasibility of our new flexible PET detection module design.Read moreRead less